Varian Medical Systems' share price is virtually unchanged from two years ago. That's despite the growing consensus that its proton therapy offers more precise and less toxic treatment for cancer patients than traditional radiation. It's now planning to spin off its imaging components business to help unlock some of that value.
Med tech is attracting a huge range of strategic investors right now. Healthcare is almost universally recognized as in need of rationalization--the application of technology in the effort to achieve better outcomes at lower costs. Medical devices and diagnostics, and the data that they generate, are expected to be central to achieving that goal in the coming decades.
Johnson & Johnson has pledged annual growth for its medical device business of about 4% to 6% through 2020. To drive that, it's looking to further enhance its fastest growing market segments while getting to market in surgical robotics and entering structural heart devices, the company told investors on May 18.
Genomic test prep company Purigen Biosystems reeled in $18.2 million in a Series A round to support development of its benchtop testing technology.
Johnson & Johnson is slated to make its case to Wall Street on its Medical Device and Consumer businesses on May 18. The conglomerate has been under pressure from investors to spin out these groups, which are vastly underperforming its Pharmaceutical segment. J&J is bent instead on salvaging them, working to restructure Medical Devices since early this year and aiming to take action on more innovative initiatives.
GE Healthcare has been exploring ways to boost its healthcare business. In order to chart growth, the company will look inward instead of outward, CEO John Flannery said.
Nordic Capital and Avista Capital Partners acquired ConvaTec from Bristol-Myers Squibb for $4.1 billion in 2008. And they've been reportedly seeking exits for the past few years--but to no avail yet. Now, the wound care and medical products company is reportedly planning an IPO that could raise more than $1 billion.
Baxter is still working through its split from the therapeutics-focused Baxalta. The latter started trading publicly at the start of July--making the new Baxter a little less than a year old. The medical products company worked to convince Wall Street that it's on track at a May 9 meeting.
Investors are looking to place a bet on surgical robotics companies that can follow in the massive footprints of Intuitive Surgical. That company has long stood alone in the promising, but often treacherous field. Micro cap TransEnterix saw some of that Wall Street support earlier this year in advance of an expected clearance for the company's SurgiBot system.
Nevro was up 7% in early trading on news that it beat Wall Street expectations for first-quarter sales--and that it raised 2016 guidance. This is only the third full quarter that the company has reported sales since its Senza Spinal Cord Stimulation System to treat chronic pain was approved by the FDA last May.